Protection against protozoan parasite Trypanosoma cruzi has been shown to be dependent on the induction of type 1 immune responses. Replication-deficient human type 5 recombinant adenoviruses have an unsurpassed ability to induce type 1 immune responses. Thus, we constructed two type 5 recombinant adenoviruses encoding parasite antigens trans-sialidase (rAdTS) and amastigote surface protein-2 (rAdASP2). Both antigens were genetically engineered to secrete recombinant products in order to induce both optimal antibody and T cell responses. Immunizations of mice with rAdASP2 and rAdTS induced high levels of serum antibodies specific for their recombinant products. In addition, both recombinant viruses were able to elicit a biased helper T cell type 1 (Th1) cellular immune response and a substantial CD8 ؉ T cell-mediated immune response. Moreover, individual immunization with rAdASP2 or rAdTS induced high levels of protection against a challenge with live parasites. CD8 ؉ T cells mediated, at least in part, such protection. Furthermore, when combined in the same inoculum, rAdTS plus rAdASP2 induced complete protection in all animals tested, even when challenges were performed 14 weeks after the last immunization. Taking together, these results show that recombinant adenoviruses expressing TS and ASP-2 antigens of T. cruzi are interesting candidates for the development of a vaccine against Chagas' disease.
INTRODUCTION I
NFECTION WITH THE PROTOZOAN PARASITE Trypanosoma cruzi causes Chagas' disease, a neglected disease that affects more than 16 million inhabitants in Latin America. More than 300,000 new patients become infected with T. cruzi every year, and approximately 21,000 humans die annually, despite the use of drugs that have much diminished past morbidity and mortality rates. Drugs used for treatment are not effective in chronically infected individuals and parasites naturally resistant to chemotherapy have been described in various regions of Latin America (Urbina, 2001; Camandaroba et al., 2003) . Thus, vaccination should be seriously considered as an alternative approach in therapy and prophylaxis of Chagas' disease.
Protective immunity against this parasite seems to be highly dependent on the induction of CD8 ϩ T cell responses and interferon (IFN)-␥, similarly to what was also found for the preerythrocytic stages of Plasmodium species, or for Toxoplasma gondii infections. CD4 ϩ T cells with a helper T cell type 1 (Th1) cytokine secretion profile and antibodies have also been described as mediators of protection against all these diseases (Brener and Gazzinelli, 1997; Rodrigues et al., 2003) . Therefore, the development of a vaccine against T. cruzi should aim at the induction of broad immunity against parasitic antigens.
Several studies attempted to develop a vaccine using live attenuated (Menezes, 1968) or killed T. cruzi parasites (Basombrio, 1990) . Even related trypanosomatids, such as the tomato parasite Phytomonas serpens (Pinge-Filho et al., 2005) , which shares common antigens with T. cruzi, have been tested as inducers of cross-protection. Unfortunately, most of these immunizations were only able to delay manifestations of the disease or at best decrease the associated pathology. Long-term protection could be achieved only when using Th1-driving adjuvants (Hoft and Eickhoff, 2005) and/or better characterized DNA subunit vaccines encoding a few parasite antigens (Sepulveda et al., 2000; Schnapp et al., 2002; Fralish and Tarleton, 2003) . When subunit plasmid DNA vaccines were used, two of the most successful candidate antigens tested were trans-sialidase (TS) and amastigote surface protein-2 (ASP-2) (Costa et al., 1998; Fujimura et al., 2001; Garg and Tarleton, 2002; Boscardin et al., 2003; Fralish and Tarleton, 2003; Vasconcelos et al., 2004) . TS is a trypomastigote-expressed antigen that catalyzes the transfer of sialic acids from host glycoconjugates to acceptor molecules on the plasma membrane of the parasite (Schenkman et al., 1994) ; ASP-2 is a surface amastigote antigen (Low et al., 1998) with a yet undescribed function.
Recombinant viruses have been shown to be particularly effective for vaccine delivery purposes . Clinical trials of new recombinant viral vaccine candidates for malaria, tuberculosis, or acquired immunodeficiency syndrome (AIDS) have shown unprecedented levels of cellular immunity against the recombinant products expressed by viral vectors, compared with preceding vaccine formulations based on purified recombinant proteins or plasmid DNA vaccines. An advantage of using some recombinant viruses is the universal adjuvant effect displayed by the viral particle itself, something that would avoid the need of using adjuvants or cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin (IL)-12. Thus, recombinant adenoviruses, influenza viruses, or vaccinia viruses display profound immunemodulating properties (Molinier-Frenkel et al., 2003; Guillot et al., 2005) . Advantageously, replication-deficient viruses limit these additional adjuvant effects to the first round of infection, and are not expected to induce prolonged generalized systemic immune-stimulatory effects that could have deleterious consequences.
We report in this paper the construction of two replicationdeficient T. cruzi recombinant adenoviruses, encoding genetically modified TS and ASP-2 antigens. We tested their ability to induce long-term immunity and protection against a lethal challenge with T. cruzi parasites. Results indicate that these adenoviral vectors represent a promising strategy to develop a vaccine for Chagas' disease.
MATERIALS AND METHODS

Mice, parasites, and hemoculture
BALB/c, C57BL/6, and C57BL/6 CD8 ϩ knockout (CD8 ϩ KO) mice were housed and handled at the animal breeding facilities of the Federal University of Minas Gerais (Centro de Bioterismo [CEBIO] , Belo Horizonte, Brazil) or the Oswaldo Cruz Foundation (FIOCRUZ-BIOTEX) according to approved institutional guidelines. Vaccine challenges were performed with 100 bloodstream trypomastigotes of the Y strain of T. cruzi obtained from Swiss mice infected 7 days previously. Parasite development was monitored in the blood according to standard methods (Krettli and Brener, 1976) . Mouse mortality was recorded daily. For hemoculture, aliquots of 0.1 ml of blood were collected and cultured in duplicate, at 28°C for 1 month in axenic liver infusion tryptose medium. Parasite growth was monitored weekly by microscopy.
Cell lines
The cell line 293 (ATCC CRL-1573) is transformed with the adenoviral E1 genomic region that was used for generation, amplification, and characterization of all the E1 replication-deficient recombinant adenoviruses (Shaw et al., 2002) . Cells were grown in Dulbecco's modified Eagle's medium (DMEM; Sigma, St. Louis, MO) supplemented with 5% fetal bovine serum (FBS; Invitrogen GIBCO, Grand Island, NY) and antibiotics.
Recombinant adenoviruses and immunization
Construction of rAdlacZ, a recombinant adenovirus carrying the Escherichia coli ␤-galactosidase-coding sequence, was described previously, together with the detailed methodology followed in this study for generation and purification of all viruses (Bruna-Romero et al., 1997) . pAdCMV-TS is a transfer plasmid that contains a eukaryotic expression cassette formed by the cytomegalovirus immediate-early promoter and the simian virus 40 (SV40) RNA polyadenylation sequences. Inside this cassette we cloned DNA sequences encoding the signal peptide and catalytic domain of T. cruzi TS protein, obtained by restriction enzyme digestion of plasmid p154/13 (Costa et al., 1998) . Equivalently, pAdCMV-ASP2 encodes ASP-2 sequences obtained by restriction digestion of plasmid pIgSPclone9 .
Mice were inoculated subcutaneously in the tail base with 100 l of viral suspension consisting of RPMI supplemented with 1% normal mouse serum containing 10 8 plaque-forming units (PFU) of each adenovirus. Immunizations were performed twice with a 6-to 8-week interval.
ELISA, Western blot, and lytic antibody detection
Recombinant TS or ASP-2 proteins were produced in Escherichia coli as previously described (Ribeirao et al., 1997; Boscardin et al., 2003) . Antibodies against those proteins were detected by enzyme-linked immunosorbent assay (ELISA) as previously described (Costa et al., 1998; Boscardin et al., 2003) . Each serum sample was analyzed in serial dilutions and individual titers were considered as the highest dilution of serum that presented an optical density at 492 nm (OD 492 ) higher than 0.1. Results are presented as mean logarithmic antibody titers Ϯ standard deviation (SD) of six animals per group.
293 cells mock-infected or infected with rAdTS, rAdASP2, or rAdlacZ at a multiplicity of infection (MOI) of 1 were collected 24 hr after infection and their extracts were analyzed by Western blot. Membranes were incubated with a pool of mouse sera specific for ASP-2 or TS followed by incubation with peroxidase-conjugated goat anti-mouse IgG antibody. Detection was performed by membrane exposure to X-ray film after a standard chemiluminescence reaction (ECL detection system; GE Healthcare, Piscataway, NJ).
Immunofluorescence reactions were performed by incubating sera of mice immunized with rAdlacZ, rAdTS, rAdASP2, or a mixture of the latter two with T. cruzi trypomastigotes and amastigotes air dried onto glass slides. Secondary fluorescein isothiocyanate (FITC)-conjugated anti-mouse antibodies were used to reveal the results of the reactions. Samples were analyzed by ultraviolet (UV) light microscopy. The presence of lytic antibodies in the sera of immunized mice was determined essentially as described (Krettli and Brener, 1976) .
Determination of IFN-␥ in spleen cell supernatants
BALB/c or C57BL/6 mice were immunized as described above. Two weeks after the last immunization, splenocytes were isolated and restimulated with 2.5-g/ml (TS) or 1-g/ml (ASP-2) protein solutions. After 3 days, supernatants were collected for cytokine determination. IFN-␥ concentration in supernatants was estimated by capture ELISA, using antibodies and recombinant cytokine purchased from BD Biosciences Pharmingen (San Diego, CA) exactly as described previously (Rodrigues et al., 1999) . Supernatants were diluted up to 10 times for a precise estimate of cytokine concentration. Cytokine concentration in each sample was determined from standard curves performed in parallel with known concentrations of recombinant mouse IFN-␥. The detection limit of the assays was 0.2 ng/ml.
Enzyme-linked immunospot assays
Enzyme-linked immunospot (ELISPOT) assays were performed as previously described (Bruna-Romero et al., 2001) . Briefly, 1.5 ϫ 10 5 splenocytes from normal BALB/c or C57BL/6 mice were used as antigen-presenting cells (APCs) after preincubation with H-2K d TS peptide IYNVGQVSI (amino acids 359-367) or H-2K b ASP-2 peptide VNHRFTLV (amino acids 552-559). APCs were added to Multiscreen HA nitrocellulose plates (Millipore, Bedford, MA) coated with anti-IFN-␥ antibody R4-6A2 (BD Biosciences Pharmingen). Responder cells, isolated from immunized or control mice 2 weeks after the last immunization, were added to the same wells at various dilutions. After incubation, plates were extensively washed and incubated with a biotinylated anti-mouse IFN-␥ antibody (XMG1.2; BD Biosciences Pharmingen) followed by peroxidase-labeled streptavidin. Reactions were developed by adding a peroxidase substrate to the wells (50 mM Tris-HCl [pH 7.5], containing 3,3Ј-diaminobenzidine tetrahydrochloride [1 mg/ml] and 30% hydrogen peroxide solution [1 l/ml]) and stopped under running water before the spots were counted with a stereomicroscope.
In vivo cytotoxicity assays and flow cytometric analyses
In vivo cytotoxicity assays were performed according to the technique described by Oehen and Brduscha-Riem (1998) . Briefly, BALB/c or C57BL/6 spleen cells were divided into two populations and labeled with the fluorogenic dye carboxyfluorescein diacetate succinimidyl diester (CFSE) at a concentration of 10 M (CFSE high ) or 1.0 M (CFSE low ). BALB/c and C57BL/6 CFSE high cells were pulsed for 40 min at 37°C with the H-2K d TS peptide (IYNVGQVSI) or with the H-2K b ASP-2 peptide (VNHRFTLV), respectively. CFSE low cells remained unpulsed. Subsequently, CFSE high cells were washed and mixed with equal numbers of CFSE low cells before intravenously injecting 2 ϫ 10 7 total cells per mouse. Recipient mice were BALB/c, C57BL/6, or CD8 ϩ knockout C57BL/6 mice, 2 weeks after the second immunization with rAdlacZ, rAdTS (BALB/c), or rAdASP2 (C57BL/6 and CD8 ϩ KO). Spleen cells of recipient mice were collected 20 hr after transfer, fixed, and analyzed by fluorescence-activated cell sorting (FACS), using a FACSCalibur cytometer (BD Biosciences Immunocytometry Systems, Mountain View, CA). The percentage of specific lysis for each peptide was determined with the following formula: 1 Ϫ [(%CFSE high infected Ϫ %CFSE low infected)/(%CFSE high naive Ϫ %CFSE low naive)] ϫ 100.
Statistical analyses
Differences in parasitemia among the different groups of mice were determined by Mann-Whitney U test (two-tailed) for nonparametric samples. Mortality rates were compared by log-rank test.
RESULTS
Generation and characterization of recombinant adenoviruses expressing T. cruzi antigens
Amastigote surface protein-2 (rAdASP2) and the enzyme trans-sialidase (rAdTS) were selected for generation of recombinant adenoviruses on the basis of earlier studies in which successful vaccination was achieved with plasmid DNA as vectors (Costa et al., 1998; Boscardin et al., 2003) . rAdASP-2 encodes the mouse immunoglobulin chain signal peptide (MQVQ-IQSLFLLLLWVPGSRG) fused to amino acids 1-694 of ASP-2. rAdTS was engineered to encode the functional native protein signal peptide (amino acids 1-33) and the entire catalytic domain of TS (amino acids 34-678) (Costa et al., 1998; Boscardin et al., 2003) (Table 1 ). The resulting recombinant ASP-2 or TS proteins do not contain glycosylphosphatidyl-inositol (GPI)-anchoring motifs, impeding any GPI anchor modification of the nascent polypeptides (Fig. 1A) . In addition to these viruses, rAdlacZ was used as control in all experiments. The capacity of infected cells to express ␤-galactosidase as well as the viral infectivity of rAdlacZ had been previously determined (Bruna-Romero et al., 1997) . The resulting replicationdeficient viruses were first used to infect cells in vitro. Extracts of those cells were tested in Western blot assays. As shown in Fig. 1B , ASP-2 or TS proteins were abundantly produced in cells infected with rAdASP2 or rAdTS, respectively. It is worth noting that four peptide products from rAdTS-infected cells reacted with anti-TS antibodies, the highest molecular weight band displaying the predicted molecular weight for the fulllength recombinant product (66 kDa). Lower molecular weight bands that react with the same TS-specific serum must represent proteolytic products that keep native antibody epitopes. Because we have previously shown that the absence of GPI-anchoring motifs increases proteolytic processing and favors antigen-loading onto MHC molecules for presentation to T cells , the proteolytic products observed for the GPI-deleted form of TS used in our study could favor its presentation to T cells.
Antibody immune responses after vaccination with rAdASP2 or rAdTS
To determine the capacity of rAdTS or rAdASP2 to elicit antibody responses against T. cruzi antigens, mice of two different genetic backgrounds were immunized with these recombinant viruses. Sera from these mice were initially analyzed by immunofluorescence to test their specificity to react with T. cruzi parasites. Figure 2A shows that sera from mice immunized with rAdTS specifically reacted with T. cruzi trypomastigotes and sera from AdASP2-immunized mice specifically reacted with amastigote forms of the parasite.
Specific IgG antibody titers in the sera of immunized mice were also determined by ELISA, using recombinant TS or ASP-2 as antigen. Antibody titers in the sera of BALB/c (H-2 d ) and C57BL/6 (H-2 b ) mice immunized with either rAdTS or rAdASP2, or a mixture of both, are shown in Fig. 2B and C, respectively. Immunization with either rAdTS or rAdASP2, or a mixture of both, resulted in IgG antibodies specific to the corresponding antigen. In contrast, control animals immunized with rAdlacZ had negligible antibody immune responses against either ASP-2 or TS (titers less than 10 2 ). No significant complement-mediated lytic activity was detected in the sera of immunized mice compared with mice infected with T. cruzi (Fig. 2D) . Comparison of serum IgG levels revealed that antibody titers against TS in BALB/c mice were higher than those detected in C57BL/6 mice. The levels of antibodies to ASP-2 were similar in mice of different genetic backgrounds. Antibody titers to TS were significantly higher than the titers to ASP-2 in both mouse strains analyzed. Importantly, animals immunized with a mixture of both viruses simultaneously (rAdTS ϩ rAdASP2) mounted antigen-specific responses of similar magnitude against each of the proteins, compared with those detected when recombinant viruses were administered individually.
Type 1 immune response after vaccination with rAdASP2 or rAdTS
Because protection against T. cruzi has been repeatedly shown to be mediated by type 1 immune responses, mediated by CD4 ϩ and CD8 ϩ T cells, we evaluated in vitro IFN-␥ production by splenic cells from BALB/c and C57BL/6 mice im- munized with rAdTS and rAdASP2, respectively. Initially, we determined the levels of IFN-␥ secreted by spleen cells after in vitro restimulation with recombinant proteins. As previously reported by one of us, IFN-␥ secreted by spleen cells in this in vitro assay is dependent on the activation of CD4 ϩ but not CD8 ϩ T cells (Rodrigues et al., 1999; Boscardin et al., 2003; Vasconcelos et al., 2004) . As shown in Fig. 3A , when restimulated in vitro with the corresponding recombinant protein, splenocytes from mice immunized with either rAdTS or rAdASP2 secreted IFN-␥. This IFN-␥ production suggests that these cells must have expanded after immunization with the recombinant viruses because splenocytes from control mice immunized with rAdlacZ secreted little or no IFN-␥ when restimulated in vitro with recombinant TS or ASP-2. The presence of type 1 CD8 ϩ T cells in mice immunized with rAdTS or rAdASP2 was determined by ex vivo ELISPOT to detect IFN-␥-producing splenocytes. BALB/c and C57BL/6 splenic cells were restimulated in vitro with the TS-derived H-2 d synthetic peptide IYNVGQVSI or with the ASP-2-derived H-2 b peptide VNHRFTLV, respectively. Previous studies established that only CD8 ϩ T cells of those mouse strains (Low et al., 1998; Rodrigues et al., 1999) recognized these peptides. As can be observed in Fig. 3B, significant 
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Ȥ mice immunized with the corresponding recombinant viruses. On the other hand, in control mice immunized with rAdlacZ no peptide-specific IFN-␥-secreting splenic cells were detected ex vivo by ELISPOT assay (data not shown). In addition to the ex vivo ELISPOT assay, we determined the presence of antigen-specific cytotoxic cells, using an in vivo assay. For this purpose, splenocytes from normal mice were labeled with various concentrations of the vital dye CFSE. The population of cells containing the highest amount of fluorescent label (CFSE high ) was then incubated with the TS-derived H-2 d synthetic peptide IYNVGQVSI or with the ASP-2-derived H-2 b peptide VNHRFTLV to be used as target cells during the assay. Equivalent amounts of CFSE low and CFSE high cells, that is, control or target cells preincubated with each relevant peptide, were mixed before being inoculated in groups of BALB/c mice immunized with rAdTS or rAdlacZ (control) or in groups of C57BL/6 mice immunized with rAdASP2 or rAdlacZ (control). The numbers of CFSE low and CFSE high fluorescent cells that remained in the spleens of the animals 20 hr after injection were determined by FACS analysis, and the percentage of specific cell lysis was determined for each group of animals. Figure 3C shows a representative result of the in vivo analyses of cytotoxic activity against target cells presenting the TSderived peptide. As can be observed in Fig. 3C , the frequencies of CFSE low and CFSE high cells were equivalent in mice immunized with a control virus (top left). Conversely, mice immunized with rAdTS (Fig. 3C, middle left) displayed a much lower frequency of CFSE high cells when compared with frequency number of CFSE low cells, indicating that the cytotoxic activity of the lymphocytes present in the rAdTS-immunized mice was eliminating those cells presenting the TS-derived peptide. The lytic activity displayed in vivo by the lymphocytes of the rAdTS-immunized mice (Fig. 3C, bottom left) represented ϳ40%. The panels on the right in Fig. 3C In vivo cytotoxicity assay of BALB/c (left) or C57BL/6 (right) mice immunized with recombinant adenoviruses rAdlacZ (assay control), rAdTS, or rAdASP2. Two weeks after the last immunization, normal splenocytes labeled with two concentrations of CFSE (CFSE high and CFSE low ) were inoculated intravenously into the tail vein of immunized mice. CFSE high cells were pulsed with peptides representing either the CD8 ϩ T cell epitope of TS (BALB/c) or ASP-2 (C57BL/6). CFSE low cells were unpulsed and served as internal controls. Percentage of specific cell lysis was measured 20 hr later by FACS and is expressed (bottom) as the mean ϩ SD of three animals per group. displayed stronger cytotoxic activity against cells presenting the ASP2-derived peptide. The lytic activity displayed by the lymphocytes of these mice reached ϳ90% (bottom right).
Protective immunity induced by vaccination with adenoviral vectors
The most definitive assays with which to test the efficiency of a vaccine are those that determine protective immunity after challenge with infective parasites. To gain insights concerning the real capacity of our recombinant vaccines to induce protective immunity against experimental Chagas' disease, BALB/c mice were immunized with control or relevant viruses. Vaccinated mice were challenged 9 weeks after administration of the last immunizing dose with 100 T. cruzi Y strain bloodstream trypomastigotes. Figure 4A shows that mice immunized with rAdlacZ displayed a high number of parasites in their blood at the time of peak parasitemia, that is, 8 days after the challenge, whereas mice that received rAdTS or rAdASP2 displayed significantly lower parasitemia (p Ͻ 0.01). Moreover, parasites were almost undetectable in mice immunized with rAdTS plus rAdASP2 (p Ͻ 0.001). The parasitemia of the various groups of mice were monitored until day 86, and no increase was observed during that period (data not shown).
Survival rates were also determined in the various groups of immunized BALB/c mice after the challenge (Fig. 4B) . In clear correlation with the results of parasitemia shown above, animals injected with rAdlacZ (control virus) died quickly, before day 20 after the challenge. In contrast, approximately 50% of the animals immunized with rAdTS (p Ͻ 0.01) and 80% of those immunized with rAdASP2 (p Ͻ 0.01) survived the challenge. No statistically significant differences in survival rates were found between these two groups. However, inoculation with a mixture of both recombinant viruses simultaneously induced protective immune responses that seemed complementary, providing resistance to 100% (p Ͻ 0.001) of all immunized animals against a challenge with T. cruzi.
Hemoculture analyses were performed in surviving mice 6 months after the challenge. All mice (100%) immunized with rAdASP2 were found to harbor live parasites. However, we found that 60% of mice immunized with rAdTS and 40% of mice immunized with rAdTS plus rAdASP2 had no parasites in their blood. These results showed that the immunity elicited by vaccination was sterilizing in a significant number of animals vaccinated.
Protective vaccination can also be induced in C57BL/6 mice and is dependent on CD8 ϩ T cells
In earlier studies, genetic immunization with ts or asp-2 genes elicited protective immunity against T. cruzi infection (Costa et al., 1998; Garg and Tarleton, 2002; Boscardin et al., 2003; Fralish and Tarleton, 2003) . Evaluation of the possible mechanisms of protection failed to correlate protective immunity with the levels of specific antibodies (Fujimura et al., 2001; Boscardin et al., 2003; Vasconcelos et al., 2004) . As opposed to antibodies, the type 1 immune response mediated by IFN-␥-producing CD4 ϩ and CD8 ϩ T lymphocytes has been linked to protection against T. cruzi Vasconcelos et al., 2004) . To discriminate the importance of CD8 ϩ T cells after vaccination with rAdTS and rAdASP2, we immunized C57BL/6 and C57BL/6-isogeneic CD8 ϩ KO mice with rAdTS and rAdASP2 before challenge with blood forms of T. cruzi.
The numbers of parasites in the blood detected at the time of peak parasitemia in C57BL/6 mice are shown in Fig. 5A . Those numbers were lower in samples collected in C57BL/6 mice injected with either rAdTS or rAdASP2. Interestingly, mice immunized with both viruses displayed significantly lower parasitemia than did mice immunized with rAdTS alone (p Ͻ 0.01), similar to what was observed in BALB/c mice. However, the difference was not found to be statistically significant in this mouse strain when we compared rAdASP2 with rAdTS plus rAdASP2. Figure 5 also shows the levels of parasitemia in CD8 ϩ KO mice immunized with either rAdTS or rAdASP2. As can be observed, immunized CD8 ϩ KO animals displayed significantly higher levels of parasites in their blood when com- pared with their immune-competent counterparts. These results confirmed that CD8 ϩ immune T cells are involved in protective immunity after immunization with recombinant virus rAdTS or rAdASP2 and support our previous observations about an additive protective effect conferred by simultaneous immunization with adenoviruses encoding two different antigens. Analysis of survival rates of the different groups of mice revealed that approximately half of C57BL/6 mice immunized with rAdlacZ (control virus) survive a challenge with live parasites whereas, significantly (p Ͻ 0.05), 90% of animals die in the absence of CD8 ϩ cells. Immunization with rAdTS and rAdASP2 conferred a high degree of protection, that is, 84 and 100%, respectively. Complete protection (100% survival) was also achieved when both viruses were administered in the same inoculum. These results confirmed that the antigens used in our study could also induce protection in animals of the C57BL/6 background. Moreover, protection seemed highly dependent on the presence of CD8 ϩ cells in both cases, because CD8 ϩ KO animals immunized with either of these two viruses were significantly less protected that their immune-competent counterparts.
Long-term immunity is induced after immunization with recombinant adenoviruses
In the development of a vaccine, it is of key importance to determine its capacity to induce long-term protective immunity against infection. Complementary to the data presented above are the percentages of protection determined in mice of different genetic backgrounds challenged at different times after the last immunizing dose with the recombinant adenoviruses. As shown in Table 2 , death after a challenge was prevented in 100% of the mice vaccinated with rAdASP2 plus rAdTS when tested 6, 9, or even 14 weeks after administration of the last immunizing dose of the recombinant adenoviruses. Lower, although maintained throughout the study, protective immunity could also be observed in mice immunized with rAdTS or rAdASP2.
DISCUSSION
It is now widely accepted that generation of vaccines against parasites with intracellular life stages such as Leishmania species, Toxoplasma gondii, Plasmodium species, or T. cruzi will require the induction of potent type 1 T cell immune responses to elicit complete and sustained protection (Brener and Gazzinelli, 1997; Denkers and Gazzinelli, 1998; Rodrigues et al., 2003) . Research on these new vaccines has been hampered by the lack of efficient means to induce cell-mediated immunity. Our results provide evidence that vaccination of mice with recombinant adenoviruses expressing two distinct T. cruzi antigens stimulates not only specific antibody-secreting B cells but also type 1 IFN-␥-producing and/or cytotoxic T cells. Also, vaccination with recombinant adenoviruses led to a significant de- crease in peak parasitemia and increase in mouse survival after a lethal challenge with trypomastigotes. Protective immunity was observed in both mouse strains tested (BALB/c and C57BL/6) and could be detected for as much as 14 weeks after the last immunizing dose. The most relevant observation of our study was the fact that in mice immunized simultaneously with both recombinant viruses, we observed complete and longlasting protection against experimental infection.
Our results confirm and extend a number of studies showing that human type 5 recombinant adenoviruses are excellent antigen-encoding gene transfer vectors, capable of inducing both cellular and humoral protective immune responses (Bruna-Romero et al., 2001; Shiver et al., 2002; Rocha et al., 2004; Tatsis and Ertl, 2004) . Also, they confirmed and extended previous studies showing that vaccination with asp-2 and ts genes elicits protective immunity against T. cruzi infection in different mouse strains against different parasite strains (Costa et al., 1998; Fujimura et al., 2001; Garg and Tarleton, 2002; Boscardin et al., 2003; Fralish and Tarleton, 2003; Vasconcelos et al., 2004) . Miyahira and colleagues (2005) reported protection against T. cruzi infection after vaccination with a recombinant adenovirus encoding a previously described amino acid nonamer of transsialidase surface antigen (TSSA) that represents a CD8 epitope in C57BL/6 mice, followed by a second immunization with a recombinant vaccinia virus encoding the same antigen. The levels of protection induced by their viral constructs were clear but modest. In the present study we went several steps forward by using two different long polypeptide antigens for immunization. As already observed in other parasitic infections such as malaria (Wang et al., 2004) , the combined use of antigens seems to be an advantage when fighting parasitic diseases, especially when those parasites have different stages in their life cycle.
Our previous (Vasconcelos et al., 2004) and present results suggest that pronounced protective immunity against T. cruzi can be achieved by using a combination of a trypomastigotederived antigen such as TS and an amastigote-derived antigen such as ASP-2. It is noteworthy that similar levels of antibodies were elicited against each protein after individual or combined immunizations (see Fig. 2B and C) . Consequently, it is feasible to believe that the augmented levels of protection observed after simultaneous administration of both viruses (see, e.g., Fig. 5A and B) result from the presence of the two antigens of interest and are not due to an increased adjuvant effect of a double dose of adenoviral vector.
The development of human vaccines based on a single epitope, that is, those constructed by Miyahira and colleagues, would plausibly be constrained by the marked degree of genetic heterogeneity of human beings. In sharp contrast, the use of antigenic proteins harboring a more complete array of B and T cell epitopes, and belonging to two distinct parasitic life stages, would allow a more efficient elimination of the parasite from entire human populations as well as confer more effective crossprotection against diverse strains of T. cruzi.
Several authors have demonstrated the key importance of CD8 ϩ T lymphocytes for protection against T. cruzi (Hoft et al., 2000; Rodrigues et al., 2003; Martin and Tarleton, 2004) . Protection mediated by CD8 ϩ T cells takes place via two different antiparasitic mechanisms: (1) secretion of large amounts of cytokines (e.g., IFN-␥) that act on the infected host cell by activating protective molecular mechanisms such as inducible nitric oxide synthase (iNOS)/nitric oxide (Holscher et al., 1998; Hoft and Eickhoff, 2005) , and (2) activation of cytolytic activities that can eliminate infected cells by releasing molecules (e.g., granzyme B or perforin) with the ability to form pores in the cell or parasite membranes (Nickell and Sharma, 2000) . We show in this paper that immunization with the recombinant viruses constructed induces high levels of T. cruzi TS-and ASP-2-specific CD8 ϩ IFN-␥-producing T lymphocytes. Furthermore, those cells displayed potent cytolytic activity, being able to lyse, in vivo, cells coated with T. cruzi peptides. In addition, immunizations with TS plus ASP-2 antigens elicited solid protection levels, both in BALB/c and C57BL/6 mice. Thus, 100% of BALB/c mice immunized with a mixture of rAdASP2 and rAdTS survived a deadly challenge with live T. cruzi parasites for more than 5 months of study and 100% of C57BL/6 mice equivalently immunized survived a similar challenge for more than 3 months of study.
It is worth noting that these experiments provide the proofof-concept that vaccination against T. cruzi may be possible, because most of the challenges were performed 2 and 3 months after receiving the last immunogen, something never performed previously and that confirms the presence of parasite-specific long-lived immune memory cells in those animals. Using CD8 ϩ KO mice, we could confirm that protection was mediated at least in part by CD8 ϩ T cells. Whereas 100% of common C57BL/6 mice immunized with rAdASP2 survived the challenge, only 30% of the CD8 ϩ KO isogeneic mice did. CD8 ϩ T cells also partially mediated protection induced by immunization with TS. Both the results of parasitemia and survival VACCINATION WITH RECOMBINANT ADENOVIRUSES AGAINST T. cruzi 9 postchallenge showed that CD8 ϩ T cells are profoundly involved but not acting alone, because knockout mice were just slightly different from their immune-competent counterparts (in parasitemia, p Ͻ 0.05 for both rAdTS and rAdASP2), suggesting that other complementary immune mechanisms may be also acting, although these are not mediated by lytic antibodies, because no T. cruzi-specific complement-mediated lytic activity was detected in the sera of immunized animals. Many authors have detected CD8 ϩ T cell responses during natural T. cruzi infections. However, these CD8 ϩ T cell-mediated immune responses were unable to completely eliminate the parasites. One of the possible explanations why the CD8 ϩ responses detected in vivo against T. cruzi do not protect against natural infection is the dispersion of CD8 ϩ responses to multiple epitopes. As suggested by Martin and Tarleton (2004) for the case of T. cruzi and by many other authors for other diseases, flooding the MHC presentation pathway with all the parasite antigens (more than 10,000 in the case of T. cruzi) may imply that the density of any individual peptide-MHC complex on the host cell surface will be below the threshold necessary to efficiently activate CD8 ϩ T cells specific for that epitope. In our case we may have been successful in vaccination because we have used only a few CD8 epitopes, something that has probably focused the immune response. Focusing the immune response may be a better choice because the expansion of a few clones of naive cells that can respond to high levels of the corresponding antigens can be achieved faster that the expansion of many clones with lower levels of expression of their multiple corresponding antigens.
In conclusion, our present work shows that only two inoculations of recombinant adenoviruses encoding a few carefully selected protective antigens are sufficient to induce high and sustained levels of immunity against T. cruzi. Our results open the possibility for testing our protocol in an animal model closer to humans that is already available (i.e., rhesus monkeys; Carvalho et al., 2003) and, because previous works (Dumonteil et al., 2004; Zapata-Estrella et al., 2006) have demonstrated the feasibility of using DNA vaccines for therapeutic purposes, future studies on the beneficial effect of this kind of vaccines for chronically infected animals are also being considered.
